Prothena (PRTA)
(Delayed Data from NSDQ)
$21.13 USD
-0.55 (-2.54%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $21.14 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 321 - 332 ( 332 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Initiating Coverage with OUTPERFORM Rating, $18 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Initiating Coverage with OUTPERFORM Rating, $18 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
We launch coverage with a Buy and a $16 target.
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R